不幸的是，TAF 目前没有
批准用于失代偿 CTP B 类患者
和 C 肝硬化由于缺乏安全性和有效性数据
(32) 然而，鉴于有限的
关于 TAF 代谢的可用数据，(33) 更新
指导文件确实承认“TAF 没有
在失代偿期肝硬化患者中进行了研究，
因此限制了在这些研究中使用 TAF 的建议
天。 但是，应考虑 TAF 或恩替卡韦
失代偿期肝硬化患者
功能障碍和/或骨病。”(1)
Unfortunately, TAF is not currently
approved for patients with decompensated CTP class B
and C cirrhosis due to the lack of data on safety and effi-
cacy in this population.(32) However, given the limited
data available regarding TAF metabolism,(33) the updated
guidance document does acknowledge that “TAF has not
been studied in patients with decompensated cirrhosis,
thus limiting recommendations to use TAF in these pa-
tients. However, TAF or entecavir should be considered
in patients with decompensated cirrhosis who have renal
dysfunction and/or bone disease.”(1)作者: chaojiwanglei 时间: 2022-1-26 17:39